Home / Technology / AI Race Risks Safety: Pharma's Regulatory Path
AI Race Risks Safety: Pharma's Regulatory Path
11 Sep
Summary
- AI development mirrors early pharmaceutical risks and necessitates regulation.
- Fatal drug accidents spurred stricter regulations, creating a pharma-industry pact.
- AI's evolving dangers, like cyberattacks, could trigger severe future rules.
The current era of artificial intelligence development, characterized by rapid progress, is increasingly necessitating regulatory oversight. This mirrors the trajectory of the pharmaceutical industry, which evolved from a self-policed stage to strict regulation following tragic accidents.
Early in drug development, voluntary regulations were common until a fatal incident in 1937 involving a poisonous solvent killed over 100 people. Subsequent accidents led to more rigorous rules, establishing a framework where therapeutic benefit must outweigh risks in exchange for market exclusivity.
Similarly, AI is currently in a volatile, self-regulated phase. Concerns about the race towards self-improving AI models have been voiced by researchers, prompting discussions about slowing development. Lawmakers are beginning to mobilize, recognizing the need for government intervention amidst uncertainty.
Drawing parallels with pharmaceuticals, AI regulation could involve mandatory licensing through rigorous testing and safety trials. While AI's abstract dangers differ from drugs' biological symptoms, and testing itself can be risky, the potential for severe consequences like cyberattacks or bioweapon creation looms large. This underscores the likelihood of intensified regulation, possibly after significant incidents occur.
